多中心篮式试验:CDK4/6抑制剂阿贝西利在复发性脑膜瘤中显示活性
该多中心篮式试验评估CDK4/6抑制剂阿贝西利治疗复发性中枢神经系统肿瘤,多数队列未见活性,但复发性脑膜瘤队列(含2/3级,19/22例)中位PFS为15个月、中位OS为32.9个月,6个月PFS为68.2%,超过RANO提出的活性基准49%。
要点
- 阿贝西利在复发性脑膜瘤中6个月PFS达68.2%,超过RANO基准49%。
- 复发性脑膜瘤队列中位PFS 15个月,中位OS 32.9个月。
- 影像学评估稳定疾病16/22例(73%),进展6/22例(27%)。
核心结论
- 数据提示阿贝西利改善晚期脑膜瘤患者的PFS和OS。
- 复发性脑膜瘤队列6个月PFS为68.2%,超过RANO提出的活性基准49%。
研究设计与样本
- 多中心篮式试验,探索CDK4/6抑制剂阿贝西利在复发性中枢神经系统肿瘤患者中的疗效。
- 纳入胶质瘤、原发性中枢神经系统淋巴瘤、脑膜瘤和室管膜瘤患者,基于初步活性证据扩展脑膜瘤队列。
- 给药方案为阿贝西利200 mg口服,每日两次,第1-28天,参照FDA乳腺癌推荐。
- 主要终点为影像学缓解率和治疗后6个月无进展生存期(PFS),同时评估总生存期(OS)和毒性。
- 探索性终点包括肿瘤活检二代测序。
主要发现
- 多数队列未显示活性,仅复发性脑膜瘤队列显示活性,该队列含2级或3级疾病患者(19/22例脑膜瘤患者)。
- 复发性脑膜瘤队列中位PFS为15个月(95%CI:6.5,未达到),中位OS为32.9个月(95%CI:10.7,未达到)。
- 复发性脑膜瘤队列6个月PFS为68.2%(95%CI:51.3%,90.7%)。
- 全部22例患者可评估影像学缓解,稳定疾病16/22例(73%),进展6/22例(27%)。
关键数值与推荐
- 复发性脑膜瘤队列6个月PFS为68.2%(95%CI:51.3%,90.7%),超过RANO提出的活性基准49%。
- 复发性脑膜瘤队列中位PFS为15个月(95%CI:6.5,未达到),中位OS为32.9个月(95%CI:10.7,未达到)。
- 影像学评估:稳定疾病16/22例(73%),进展6/22例(27%)。
临床怎么用
- 对于复发性脑膜瘤(含2级或3级疾病),阿贝西利可能改善PFS和OS,6个月PFS超过RANO活性基准。
- 治疗期间需评估影像学缓解和PFS,并监测毒性和总生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) tumors are associated with considerable morbidity and high mortality. Cyclin-dependent kinases (CDKs) regulate cell division in cancer, and CDK4/6 inhibitors are used for the treatment of breast cancer, representing an attractive therapy for different tumor types. METHODS: Here, we report mature results of a multicenter basket trial exploring the CDK4/6 inhibitor abemaciclib in patients with recurrent CNS tumors, including patients with glioma, primary CNS lymphoma, meningioma, and ependymoma. We expanded our cohort of meningioma patients based on preliminary evidence for activity. Patients were treated with 200 mg oral abemaciclib twice daily for days 1-28, following FDA recommendations for breast cancer. Primary outcomes included radiographic response rates and progression-free survival (PFS) at 6 months post-treatment. We also evaluated overall survival (OS) and toxicity. Exploratory outcomes included next-generation sequencing of tumor biopsies. RESULTS: Most cohorts did not demonstrate activity with the exception of the cohort of patients with recurrent meningioma, including patients with grade 2 or 3 disease (19/22 meningioma patients). In that group, the median PFS was 15 months (95% CI: 6.5, not reached) and median OS was 32.9 months (95% CI: 10.7, not reached); the 6-month PFS was 68.2% (95% CI: 51.3%, 90.7%). All 22 patients were evaluable for radiographic response, showing stable disease in 16/22 (73%) and progressive disease in 6/22 patients (27%). CONCLUSION: Our data suggest that abemaciclib improves PFS and OS in patients with advanced meningioma. The 6-month PFS with abemaciclib in this study (68.2%) exceeded RANO proposed benchmarks for activity (49%). TRIAL REGISTRATION: NCT03220646.
引用
- Kaley TJ, Grommes C, Coffee E, et al. Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. Neuro Oncol. 2025. PMID: 40842355. doi:10.1093/neuonc/noaf184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。